Jasper Therapeutics, Inc. (JSPR)
$0.50-10.71%Close
SELLCRISIS · day 23
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8M
- Beta
- 3.04
- P/E (TTM)
- -0.31
- Short % float
- 45.13%
- Days to cover
- 16.3
- SI change
- +7.1%
- 1W
- -10.71%
- 1M
- -20.63%
- vs SPY 1W
- -10.58%
- vs SPY 1M
- -23.14%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 11
- VALUE
- 22
- GROWTH
- 42
- GARP
- 6
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-269.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.31
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B10.07
P/FCF-
EV/EBITDA-0.03
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E19.11
ALTMAN Z-
CURR RATIO1.47
ND/EBITDA-
BETA3.04
Company news
FAQ
- What is LOPJLB’s current signal on JSPR?
- LOPJLB’s latest quantitative signal on Jasper Therapeutics, Inc. (JSPR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is JSPR in?
- Jasper Therapeutics, Inc. (JSPR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Jasper Therapeutics, Inc. (JSPR) do?
- Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The companyâs lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commerci…